Can The Generics Industry Leverage Its COVID Success To Achieve Its Policy Goals?
Vaccine makers get all the credit (among those who think any credit is due) for ending the pandemic, but generic sponsors want to remind policymakers that their plants stayed open during the worst of COVID-19 to ensure that hospitals were stocked and medicines for chronic conditions didn’t run short.
You may also be interested in...
The new chair of the US generics association talks to the Pink Sheet about how to make sure that policymakers don’t take the industry for granted.
Offering a regulatory Mt. Rushmore to place the outgoing principal deputy commissioner in historical context.
Pink Sheet reporter and editors discuss the issues and concerns raised during a major generic industry conference, former Commissioner Gottlieb’s views on what a second Trump term would mean for FDA, and congressional hearings on foreign facility inspections and drug shortages.